The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Cardiac Involvement in Fabry Disease
Open accessAbstract
Fabry disease (FD) is a rare X-linked inherited lysosomal storage disorder caused by deficient α-galactosidase A activity that leads to an accumulation of globotriasylceramide (Gb3) in affected tissues, including the heart. Cardiovascular involvement usually manifests as left ventricular hypertrophy, myocardial fibrosis, heart failure, and arrhythmias, which limit quality of life and represent the most common causes of death. Following the introduction of enzyme replacement therapy, early diagnosis and treatment have become essential to slow disease progression and prevent major cardiac complications. Recent advances in the understanding of FD pathophysiology suggest that in addition to Gb3 accumulation, other mechanisms contribute to the development of Fabry cardiomyopathy. Progress in imaging techniques have improved diagnosis and staging of FD-related cardiac disease, suggesting a central role for myocardial inflammation and setting the stage for further research. In addition, with the recent approval of oral chaperone therapy and new treatment developments, the FD-specific treatment landscape is rapidly evolving.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Fabry disease revisited: Management and treatment recommendations for adult patients
Ortiz, A., Germain, D. P., Desnick, R. J., Politei, J., Mauer, M., Burlina, A., Eng, C., Hopkin, R. J., Laney, D., Linhart, A., et al. (2018) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2018.02.014 · Cited by 650
Self-citationPastores, G. M. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00036-6 · Cited by 633
Treatment of Fabry’s Disease with the Pharmacologic Chaperone Migalastat
Germain, D. P., Hughes, D. A., Nicholls, K., Bichet, D. G., Giugliani, R., Wilcox, W. R., Feliciani, C., Shankar, S. P., Ezgu, F., Amartino, H., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510198 · Cited by 555
Rapezzi, C., Arbustini, E., Caforio, A. L. P., Charron, P., Gimeno-Blanes, J., Helio, T., Linhart, A., Mogensen, J., Pinto, Y., Ristic, A., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs397 · Cited by 439
Self-citationX‐chromosome inactivation in female patients with Fabry disease
Echevarria, L., Benistan, K., Toussaint, A., Dubourg, O., Hagege, A. A., Eladari, D., Jabbour, F., Beldjord, C., De Mazancourt, P., & Germain, D. P. (2016) · Clinical Genetics · doi:10.1111/cge.12613 · Cited by 424
Self-citationGermain, D. P., Elliott, P. M., Falissard, B., Fomin, V. V., Hilz, M. J., Jovanovic, A., Kantola, I., Linhart, A., Mignani, R., Namdar, M., et al. (2019) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2019.100454 · Cited by 233
Self-citationAn Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease
Linhart, A., Germain, D. P., Olivotto, I., Akhtar, M. M., Anastasakis, A., Hughes, D., Namdar, M., Pieroni, M., Hagège, A., Cecchi, F., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1960 · Cited by 230
Self-citationContribution of inflammatory pathways to Fabry disease pathogenesis
Rozenfeld, P., & Feriozzi, S. (2017) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2017.09.004 · Cited by 219
Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy
Burlina, A. B., Polo, G., Salviati, L., Duro, G., Zizzo, C., Dardis, A., Bembi, B., Cazzorla, C., Rubert, L., Zordan, R., et al. (2018) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-017-0098-3 · Cited by 174
Developments in the treatment of Fabry disease
van der Veen, S. J., Hollak, C. E. M., Kuilenburg, A. B. P., & Langeveld, M. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12228 · Cited by 158
Cardiac Microvascular Pathology in Fabry Disease
Thurberg, B. L., Fallon, J. T., Mitchell, R. N., Aretz, T., Gordon, R. E., & O'Callaghan, M. W. (2009) · Circulation · doi:10.1161/circulationaha.108.841494 · Cited by 150
Ortíz, A., Abiose, A. K., Bichet, D. G., Cabrera, G. H., Charrow, J., Germain, D. P., Hopkin, R. J., Jovanović, A., Linhart, A., Maruti, S. S., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103486 · Cited by 145
Self-citationLyso-Gb3 activates Notch1 in human podocytes
Sánchez-Niño, M. D., Carpio, D., Sanz, A. B., Ruiz‐Ortega, M., Mezzano, S. A., & Ortíz, A. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv291 · Cited by 142
Schiffmann, R., Göker-Alpan, Ö., Holida, M. D., Giraldo, P., Barisoni, L. M. C., Colvin, R. B., Jennette, J. C., Maegawa, G. H. B., Boyadjiev, S. A., Gonzalez, D., et al. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12080 · Cited by 141
Doheny, D. O., Srinivasan, R., Pagant, S., Chen, B., Yasuda, M., & Desnick, R. J. (2018) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2017-105080 · Cited by 137
The Role of Cardiac Imaging in the Diagnosis and Management of Anderson-Fabry Disease
Perry, R., Shah, R. J., Saiedi, M., Patil, S., Ganesan, A. N., Linhart, A., & Selvanayagam, J. B. (2019) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2018.11.039 · Cited by 128
Self-citationDeRosa, F., Smith, L., Shen, Y., Huang, Y., Pan, J., Xie, H., Yahalom, B., & Heartlein, M. W. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.001 · Cited by 111
Later Onset Fabry Disease, Cardiac Damage Progress in Silence
Hsu, T., Hung, S., Chang, F., Yu, W., Sung, S., Hsu, C., Dzhagalov, I. L., Yang, C., Chu, T.-H., Lee, H.-J., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.09.943 · Cited by 110
Electrocardiographic Changes and Arrhythmia in Fabry Disease
Namdar, M. (2016) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2016.00007 · Cited by 102
Self-citationPeterschmitt, M., Crawford, N. P. S., Gaemers, S. J. M., Ji, A., Sharma, J., & Pham, T. T. (2020) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.865 · Cited by 101
Innate and Adaptive Immune Response in Fabry Disease
Mauhin, W., Lidove, O., Masat, E., Mingozzi, F., Mariampillai, K., Ziza, J.-M., & Benvéniste, O. (2015) · JIMD Reports · doi:10.1007/8904_2014_371 · Cited by 92
Lysosomal storage disorders affecting the heart: a review
Nair, V., Belanger, E. C., & Veinot, J. P. (2018) · Cardiovascular Pathology · doi:10.1016/j.carpath.2018.11.002 · Cited by 89
Yogasundaram, H., Nikhanj, A., Putko, B. N., Boutin, M., Jain‐Ghai, S., Khan, A., Auray‐Blais, C., West, M. L., & Oudit, G. Y. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009098 · Cited by 89
Prevalence and clinical significance of red flags in patients with hypertrophic cardiomyopathy
Limongelli, G., Monda, E., Tramonte, S., Gragnano, F., Masarone, D., Frisso, G., Esposito, A., Gravino, R., Ammendola, E., Salerno, G., et al. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.06.073 · Cited by 81
Predictors of Clinical Evolution in Prehypertrophic Fabry Disease
Camporeale, A., Pieroni, M., Pieruzzi, F., Lusardi, P., Pica, S., Spada, M., Mignani, R., Burlina, A. P., Bandera, F., Guazzi, M., et al. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.118.008424 · Cited by 78
Self-citationA Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology
Birket, M. J., Raibaud, S., Lettieri, M., Adamson, A. D., Letang, V., Cervello, P., Redon, N., Ret, G., Viale, S., Wang, B., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.07.004 · Cited by 77
Lenders, M., Neußer, L. P., Rudnicki, M., Nordbeck, P., Canaan‐Kühl, S., Nowak, A., Cybulla, M., Schmitz, B., Lukáš, J., Wanner, C., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018070740 · Cited by 76
Self-citationNordin, S., Kozor, R., Vijapurapu, R., Augusto, J. B., Knott, K. D., Captur, G., Treibel, T. A., Ramaswami, U., Tchan, M. C., Geberhiwot, T., et al. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.119.009430 · Cited by 76
Self-citationImmune‐Mediated Myocarditis in Fabry Disease Cardiomyopathy
Frustaci, A., Verardo, R., Grande, C., Galea, N., Piselli, P., Carbone, I., Alfarano, M., Russo, M. A., & Chimenti, C. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009052 · Cited by 74
Lenders, M., Nordbeck, P., Kurschat, C. E., Karabul, N., Kaufeld, J. K., Hennermann, J. B., Patten, M., Cybulla, M., Müntze, J., Üçeyler, N., et al. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1832 · Cited by 71
Self-citationMyofilament Degradation and Dysfunction of Human Cardiomyocytes in Fabry Disease
Chimenti, C., Hamdani, N., Boontje, N. M., COBELLI, F. D., Esposito, A., Bronzwaer, J. G. F., Stienen, G. J. M., Russo, M. A., Paulus, W. J., Frustaci, A., et al. (2008) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070576 · Cited by 67
Warnock, D. G., Bichet, D. G., Holida, M. D., Göker-Alpan, Ö., Nicholls, K., Thomas, M., Eyskens, F. J. M., Shankar, S. P., Adera, M., Sitaraman, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134341 · Cited by 65
Quantitative Myocardial Perfusion in Fabry Disease
Knott, K. D., Augusto, J. B., Nordin, S., Kozor, R., Camaioni, C., Xue, H., Hughes, R. K., Manisty, C., Brown, L. A. E., Kellman, P., et al. (2019) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.119.008872 · Cited by 63
Self-citationYasuda, M., Huston, M. W., Pagant, S., Gan, L., Martin, S. S., Sproul, S., Richards, D., Ballaron, S. J., Hettini, K., Ledeboer, A., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.07.002 · Cited by 61
Ivanova, M. M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041116 · Cited by 57
Founder effect of Fabry disease due to p.F113L mutation: Clinical profile of a late-onset phenotype
Azevedo, O. M., Gal, A., Faria, R., Gaspar, P., Miltenberger-Miltényi, G., Gago, M. F., Dias, F., Martins, A., Rodrigues, J., Reimão, P., et al. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.07.012 · Cited by 53
Welford, R. W. D., Mühlemann, A., Garzotti, M., Rickert, V., Groenen, P. M. A., Morand, O. H., Üçeyler, N., & Probst, M. R. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy248 · Cited by 47
Crivaro, A., Mucci, J. M., Bondar, C., Ormazábal, M., Ceci, R., Simonaro, C. M., & Rozenfeld, P. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217780 · Cited by 22
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Self-citation
Metadata
- Authors
- Pieroni, M., Moon, J. C., Arbustini, E., Barriales-Villa, R., Camporeale, A., Vujkovac, A. C., Elliott, P. M., Hagege, A., Kuusisto, J., Linhart, A., Nordbeck, P., Olivotto, I., Pietilä-Effati, P., & Namdar, M.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 77
- Issue
- 7
- Pages
- 922-936
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W3131175772
- Cited by
- 340
- References
- 39
- FWCI
- 25.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.